Real-Time and Ultrasensitive Prostate-Specific Antigen Sensing Using Love-Mode Surface Acoustic Wave Immunosensor Based on MoS@CuO-Au Nanocomposites.

Prostate-specific antigen (PSA) is a well-established tumour marker for prostatic carcinoma. In this study, we present a novel, real-time, and ultrasensitive Love-mode surface acoustic wave (L-SAW) immunosensor for PSA detection enhanced by MoS@CuO-Au nanocomposite conjugation. The MoS@CuO-Au nanocomposites were analyzed by SEM, XRD, and EDS.

Silencing of secreted phosphoprotein 1 attenuates sciatic nerve injury-induced neuropathic pain: Regulating extracellular signal-regulated kinase and neuroinflammatory signaling pathways.

Background: Neuropathic pain (NP) is a chronic pathological pain that affects the quality of life and is a huge medical burden for affected patients. In this study, we aimed to explore the effects of secreted phosphoprotein 1 (SPP1) on NP.

Methods: We established a chronic constriction injury (CCI) rat model, knocked down SPP1 via an intrathecal injection, and/or activated the extracellular signal-regulated kinase (ERK) pathway with insulin-like growth factor 1 (IGF-1) treatment.

Highly Sensitive Love Mode Acoustic Wave Platform with SiO Wave-Guiding Layer and Gold Nanoparticles for Detection of Carcinoembryonic Antigens.

A highly sensitive and precise Love wave mode surface acoustic wave (SAW) immunosensor based on an ST-cut 90°X quartz substrate and an SiO wave-guiding layer was developed to detect cancer-related biomarkers of carcinoembryonic antigens (CEAs). A delay line structure of the SAW device with a resonant frequency of 196 MHz was designed/fabricated, and its surface was functionalized through CEA antibody immobilization. The CEA antibodies were bound with gold nanoparticles and CEA antibodies to form a sandwich structure, which significantly amplified the mass loading effect and enhanced the maximum responses by 30 times.

Remimazolam alleviates neuropathic pain via regulating bradykinin receptor B1 and autophagy.

Objectives: Neuropathic pain (NP) represents a broad scope of various pathological ramifications of the nervous system. Remimazolam is a proved sedative in treating neuropathic pain. Considering the Bradykinin receptor's vital role and the potentials of Bradykinin receptor B1 (BDKRB1) in the neuropathic pain-signalling pathway, we nominated them as a primary target for remimazolam.